# (PART) BODY FLUIDS {-}

# Fluids, electrolytes & acid-base

## Hyponatraemia

```{block2, type='box_landmark'}
[**Chung et al.**](https://www.ncbi.nlm.nih.gov/pubmed/3674097) (1987): ![](Logo_OBS.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - UNa discriminates between hypovolaemic (UNa \~18 mM) and eu-volaemic (UNa \~72 mM) hyponatraemia.  

```

[**SALT-1 & SALT-2**](https://www.ncbi.nlm.nih.gov/pubmed/17105757) (2006): ![](Logo_RCT.png){height=1.2em} - tolvaptan *vs.* placebo for eu- or hyper-volaemia hyponatraemia.  Tolvaptan was effective at raising serum Na^+^ in the short term (up to 30 days).  

[**EVEREST Outcome**](https://www.ncbi.nlm.nih.gov/pubmed/17384437) (2007): ![](Logo_RCT.png){height=1.2em} - tolvaptan *vs.* placebo for patients hospitalised with heart failure.  Tolvaptan had beneficial effects on short-term fluid-electrolyte status but no effect on long-term mortality or heart-failure morbidity outcomes.  
[**SGLT2i in SIAD**](https://pubmed.ncbi.nlm.nih.gov/36396331/) (2022): ![](Logo_RCT.png){height=1.2em} - empagliflozin *vs.* placebo in chronic SIAD (n = 14, cross-over, blind RCT).  Baseline Na 130 mM.  After 4 weeks, improvements in serum Na and cognitive function scores in this small study.  

## Hyperkalaemia

[**OPAL-HK**](https://www.ncbi.nlm.nih.gov/pubmed/25415805) (2015): ![](Logo_RCT.png){height=1.2em} - patiromer *vs.* placebo in patients with CKD on RASi.  Patiromer was effective at preventing hyperkalaemia.  

[**Packham et al.**](https://www.ncbi.nlm.nih.gov/pubmed/25415807) (2015): ![](Logo_RCT.png){height=1.2em} - ZS-9 (zirconium cyclosilicate) *vs.* placebo in hyperkalaemia. ZS-9 was effective at lowering potassium levels.  

[**AMBER**](https://www.ncbi.nlm.nih.gov/pubmed/31533906) (2019): ![](Logo_RCT.png){height=1.2em} - patiromer *vs.* placebo in patients with CKD and resistant HTN being treated with open-label spironolactone.  At 12 weeks, more patients in the patiromer group remained on spironolactone (86 *vs.* 66 %).  Differences in blood pressure / proteinuria not determined.  


## IV fluid therapy {#fluids}

[**SAFE**](https://www.ncbi.nlm.nih.gov/pubmed/15163774) (2004): ![](Logo_RCT.png){height=1.2em} - 4% HAS *vs.* 0.9% NaCl in ITU.  No difference in mortality at 28 days.  

[**FACCT: fluids and catheters treatment trial**](https://www.ncbi.nlm.nih.gov/pubmed/16714767) (2006): ![](Logo_RCT.png){height=1.2em} - conservative *vs.* liberal fluid strategy in acute lung injury.  Primary outcome was death at 60 days.  No difference between groups in primary outcome but conservative strategy shortened duration of ventilation / ITU stay.  

[**FEAST**](https://www.ncbi.nlm.nih.gov/pubmed/21615299) (2011): ![](Logo_RCT.png){height=1.2em} â€“ IV fluid bolus *vs.* no fluid bolus in children with severe febrile illness in East Africa (57% malaria).  48-hr mortality was higher in the fluid bolus group.  

[**SMART**](https://www.ncbi.nlm.nih.gov/pubmed/29485925) (2018): ![](Logo_RCT.png){height=1.2em} - balanced crystalloids *vs.* 0.9% NaCl in critically ill adults.  Primary outcome was composite of death, RRT or persistant SCr > 200% baseline.  Balanced crystalloid group fared better.  

```{block2, type='box_landmark'}
[**SALT-ED**](https://www.ncbi.nlm.nih.gov/pubmed/29485926) (2018): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - balanced crystalloids *vs.* 0.9% NaCl in non-critically ill adults.  Primary outcome was composite of in-hospital mortality and length-of-stay to 28 days.  No difference between groups (but less AKI in the balanced crystalloids group).  Median volume of fluids was only ~1L.  

[**RELIEF**](https://www.ncbi.nlm.nih.gov/pubmed/29742967) (2018): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - restrictive *vs.* liberal peri-operative fluid strategy. No difference in the primary outcome (disability-free survival at 1 yr); more AKI in the restrictive group.  

```

## Diuretic therapy

[**Dikshit et al**](https://www.ncbi.nlm.nih.gov/pubmed/4697939) (1973): ![](Logo_PHY.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - haemodynamic parameters studied in 20 patients given IV furosemide for LV failure after acute MI.  Within 15 mins, there was a 50% increase in peripheral venous capacitance and a 25% fall in LV filling pressure (PCWP), preceding any increase in urine output.  Therefore the immediate beneficial effects of furosemide are mediated by venodilatation. 

[**CARESS-HF**](https://www.ncbi.nlm.nih.gov/pubmed/23131078) (2012): ![](Logo_RCT.png){height=1.2em} - diuretics *vs.* ultrafiltration in acute decompensated heart failure. No difference in weight loss at 96 hrs; UF group had worse renal function and more adverse events.  

[**DOSE**](https://www.ncbi.nlm.nih.gov/pubmed/21366472) (2011): ![](Logo_RCT.png){height=1.2em} with factorial design: bolus *vs.* infusion furosemide and low- vs. high- dose in acute decompensated heart failure.  No significant differences in symptoms or SCr at 72 hrs in any group.  


## Metabolic acidosis

### Acidosis of CKD
[**de Brito-Ashurst et al.**](https://www.ncbi.nlm.nih.gov/pubmed/19608703) (2009): ![](Logo_RCT.png){height=1.2em} - oral NaHCO~3~ *vs.* standard care for 2 yrs in acidaemic CKD IV. NaHCO~3~ slowed rate of CrCl decline.  

[**Mahajan et al.**](https://www.ncbi.nlm.nih.gov/pubmed/20445497) (2010): ![](Logo_RCT.png){height=1.2em} - oral NaHCO~3~ *vs.* placebo for 5 yrs in hypertensive CKD III. NaHCO~3~ slowed rate of eGFR decline.  


### Renal tubular acidosis
[**FF test**](https://www.ncbi.nlm.nih.gov/pubmed/17410104) (2007): ![](Logo_PHY.png){height=1.2em} - furosemide-fludrocortisone test to diagnose dRTA.  


### Severe metabolic acidosis
[**BICAR-ICU**](https://www.ncbi.nlm.nih.gov/pubmed/29910040) (2018): ![](Logo_RCT.png){height=1.2em} - IV 4.2% NaHCO~3~ *vs* placebo in severe metabolic acidaemia (pH <7.2). No effect on composite primary outcome overall - but NaHCO~3~ did improve 28-day survival in (pre-specified) subgroup with AKI.  
